Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer - Trial NCT06268210
Access comprehensive clinical trial information for NCT06268210 through Pure Global AI's free database. This Phase 2 trial is sponsored by Yonsei University and is currently Not yet recruiting. The study focuses on Non-small Cell Lung Cancer. Target enrollment is 160 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Yonsei University
Timeline & Enrollment
Phase 2
Mar 01, 2024
Jun 01, 2028
Primary Outcome
Primary pathological response
Summary
In the randomized, multicenter Phase II clinical trial, we aim to evaluate the efficacy and
 safety of Lazertinib monotherapy or the combination of Lazertinib and cytotoxic chemotherapy
 as neoadjuvant therapy in patients with resectable, treatment-naive EGFR-mutant (exon 19
 deletion or exon 21 L858R) non-small cell lung cancer, ranging from clinical stage IB to
 IIIB. The study is designed to assess the impact on pathological response, as well as
 effectiveness and safety considerations.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06268210
Non-Device Trial